$NRIX

GREGORY JULIA P sold $529K of NRIX

GREGORY JULIA P sold 22,583 shares of Nurix Therapeutics, Inc. (NRIX) at $23.40 ($0.53M total) on 2026-10-14.

Original reporting
SEC EDGAR · GREGORY JULIA P
Published Oct 14, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NRIX
Bearish
medium confidence
Mentioned
$NRIX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NRIXBearishLow
01

Why it matters

The transaction is unlikely to move the stock significantly but may attract short‑term traders looking for downside bias.

02

Market read

A routine insider sale with limited market impact; traders may note the transaction but no immediate action is warranted.

03

What to watch

No pre‑arranged 10b5‑1 plan; the director may have needed liquidity for personal reasons.

Relevance 5/10Novelty 4/10Timing: same-day filing

Background

SEC Form 4 filings disclose insider transactions. Directors selling shares can be viewed as a signal, but the amount here is modest relative to market cap.

Company-level read

Ticker impact

$NRIXBearishMedium confidence
Context

Director Gregory Julia P sold 22,583 shares of Nurix Therapeutics for $528,528 on 2026-10-14, reducing his holding to 10,750 shares.

Expected impact

likely slight downward pressure as the market prices the insider's sell order

Evidence & confidence

A director sold over half a million dollars of stock, which can be interpreted as a lack of confidence and may prompt short‑term sellers.

Market effects

Minimal impact on the broader biotech sector; the sale is company‑specific.

No regional effect; the filing is a standard SEC disclosure.

None

Counterpoint

The sale could be routine portfolio rebalancing and not indicative of future performance.

Key entities

  • Nurix Therapeutics, Inc.

    Biopharma company developing targeted protein degradation therapies.

  • Gregory Julia P

    Director of Nurix Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NRIXMedAI 8/10

Nurix Therapeutics 3Q 2026: Revenue $673.1M, EPS $4.73— 10-Q Summary

Nurix Therapeutics reported Q3 2026 revenue of $673.1M, up from $7.9M YoY, driven by Roche license revenue. Net income was $549.8M, a $636.2M swing from a loss last year. Diluted EPS was $4.73. The company advanced clinical trials and expanded partnerships with Roche, Gilead, Sanofi, and Pfizer, receiving $1.2B to date with up to $7.2B in potential milestones and royalties.

$NRIXHighAI 8/10

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics, Inc. (NRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobruti